TY - JOUR
T1 - Hyperthermic isolated perfusion with low-dose TNFα and doxorubicin in patients with locally advanced soft tissue limb sarcomas
AU - Rossi, Carlo Ricardo
AU - Foletto, M.
AU - Mocellin, S.
AU - Pilati, P.
AU - Quintieri, L.
AU - De Salvo, G. L.
AU - Nitti, D.
AU - Lise, M.
PY - 2004/11
Y1 - 2004/11
N2 - We report here the results of 27 patients who underwent hyperthermic isolated limb perfusion with low-dose TNFα (1 mg) and doxorubicin (8.5 mg/l of limb volume) for locally advanced soft tissue sarcomas. A tumor response was observed in 85% of cases. After a median follow-up of 30 months, limb salvage and local disease control were achieved in 82 and 85% of patients, respectively. Locoregional toxicity was low or mild in 14 patients, while 2 patients had severe limb toxicity. Systemic side effects were negligible. The perfusate/plasma area under the curve (AUC) ratio for TNFα was 56. HILP with low-dose TNFα and DXR proved to be an active neoadjuvant drug regimen against limb-threatening STS.
AB - We report here the results of 27 patients who underwent hyperthermic isolated limb perfusion with low-dose TNFα (1 mg) and doxorubicin (8.5 mg/l of limb volume) for locally advanced soft tissue sarcomas. A tumor response was observed in 85% of cases. After a median follow-up of 30 months, limb salvage and local disease control were achieved in 82 and 85% of patients, respectively. Locoregional toxicity was low or mild in 14 patients, while 2 patients had severe limb toxicity. Systemic side effects were negligible. The perfusate/plasma area under the curve (AUC) ratio for TNFα was 56. HILP with low-dose TNFα and DXR proved to be an active neoadjuvant drug regimen against limb-threatening STS.
KW - Doxorubicin
KW - Isolated limb perfusion
KW - Locally-advanced soft tissue limb sarcomas
KW - TNFα
UR - http://www.scopus.com/inward/record.url?scp=11144248849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144248849&partnerID=8YFLogxK
M3 - Article
C2 - 15675481
AN - SCOPUS:11144248849
VL - 16
SP - 58
EP - 61
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
SN - 1120-009X
IS - SUPPL. 5
ER -